

sanofi



MyQorzo
Aficamten
– For China only

ESR Areas of Interest

Jan 2026



Aficamten areas of interest for ESR

- Divergent mechanisms underlying differential efficacy and safety profiles among Cardiac Myosin Inhibitors (CMIs)
- Evidences for Aficamten usage in special patient cohorts: such as patients with obstruction in specific anatomy position (e.g. apical hypertrophy, left ventricular mid-cavity obstruction), CMI use in post-surgery (SRT) patients etc.